Viewing Study NCT05920356

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:31 PM
Ignite Modification Date: 2026-01-01 @ 5:03 PM
Study NCT ID: NCT05920356
Status: RECRUITING
Last Update Posted: 2025-12-12
First Post: 2023-05-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer (NSCLC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Oncology View
None Lung Cancer View
None PD-L1 View
None KRAS p.G12C View
None Sotorasib View
None Pembrolizumab View
None Carboplatin View
None Pemetrexed View
None CodeBreaK 202 View
None NSCLC View
None PD-L1 Negative View
None AMG 510 View
None LUMAKRAS ® View
None LUMYKRAS ® View